Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
- The investigators evaluated the role of allopurinol in prevention of post-ERCP
pancreatitis.
- 100 Egyptian patients who were candidates for ERCP were included and divided into two
groups. Group 1 (study group) included 50 patients who received two doses of allopurinol
300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50
patients who did not receive allopurinol prophylaxis.